Sistema de Salut de Catalunya
Institut Català de la Salut
[Turner PJ] National Heart Lung Institute, Imperial College London, London, UK. Discipline of Paediatrics and Child Health, School of Medicine, University of Sydney, Sydney, Australia. [Ansotegui IJ] Dept. Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain. [Campbell DE] Discipline of Paediatrics and Child Health, School of Medicine, University of Sydney, Sydney, Australia. DBV Technologies, Montrouge, France. [Cardona V] Secció d’Al·lèrgia, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ebisawa M] Department of Allergy, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan. [El-Gamal Y] Pediatric Allergy and Immunology Unit, Ain Shams University, Cairo, Egypt
Vall d'Hebron Barcelona Hospital Campus
2022-03-14T13:23:13Z
2022-03-14T13:23:13Z
2021-02
Anafilaxi; COVID-19; Polietilenglicol
Anafilaxia; COVID-19; Polietilenglicol
Anaphylaxis; COVID-19; Polyethylene glycol
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.
Article
Published version
English
COVID-19 (Malaltia) - Vacunació; Anafilaxi; Medicaments - Efectes secundaris; CHEMICALS AND DRUGS::Complex Mixtures::Biological Products::Vaccines::Viral Vaccines; Other subheadings::Other subheadings::Other subheadings::/adverse effects; DISEASES::Immune System Diseases::Hypersensitivity::Hypersensitivity, Immediate::Anaphylaxis; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::productos biológicos::vacunas::vacunas víricas; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos; ENFERMEDADES::enfermedades del sistema inmune::hipersensibilidad::hipersensibilidad inmediata::anafilaxia; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
Elsevier
World Allergy Organization Journal;14(2)
https://doi.org/10.1016/j.waojou.2021.100517
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]
